Emerging Trends to Drive Colorectal Cancer Molecular Diagnostics Market Growth at 8.3% CAGR Through 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Colorectal Cancer Molecular Diagnostics Market Size Growth Forecast: What to Expect by 2025?
The market encompassing molecular diagnostics for colorectal cancer has experienced substantial expansion lately, projecting an increase from $2.56 billion in 2024 to $2.76 billion the following year, reflecting a compound annual growth rate of 7.9%; this upward trajectory during the past period is largely due to the rising prevalence of colorectal cancer, heightened public consciousness and screening efforts, the increasing focus on tailoring treatments to individuals, and supportive governmental programs aimed at cancer management.

How Will the Colorectal Cancer Molecular Diagnostics Market Size Evolve and Grow by 2029?
Substantial expansion is anticipated within the colorectal cancer molecular diagnostics market over the foroming years, projected to reach a monetary value of $3.79 billion by the year 2029, driven by a compound annual growth rate (CAGR) amounting to 8.3%. This upswing during the specified projection timeline stems from several contributing elements, such as an expanding elderly demographic coupled with escalating risk elements, the incorporation of genetic information into routine medical care, the growing prevalence of personalized treatment strategies, and worldwide initiatives in cancer investigation and cooperative endeavors. Key developments poised to shape this market throughout the forecast include a heightened focus on identifying biomarkers for identification at earlier stages, the adoption of artificial intelligence (AI) technologies for dissecting complex data, the growing significance of circulating tumor DNA (CTDNA) assessments, the proliferation of companion diagnostics supporting specialized treatments, and a concentrated effort on biomarkers relevant to immunotherapies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

What Drivers Are Propelling the Growth of Colorectal Cancer Molecular Diagnostics Market Forward?
The escalating prevalence of inflammatory bowel diseases (IBD) is anticipated to be the principal catalyst for the expansion of the colorectal cancer molecular diagnostic sector in the near future.IBD constitutes long-term ailments of the gastrointestinal tract, marked by inflammation chiefly concentrated in the colon and , manifesting symptoms such as cramping stomach discomfort, persistent loose stools, and unintended weight reduction, treatments for which involve pharmaceuticals, adjustments to daily habits, and occasionally surgical intervention.As the frequency of these inflammatory bowel conditions rises, so too does the need for precise, highly effective, and sophisticated diagnostic instruments, which hold critical importance because the selection of systemic treatments for colorectal cancer (CRC) is largely predicated upon the findings derived from molecular evaluation of the afflicted tissue.To illustrate this point, data released by the UK Parliament in April 2024 highlighted that a governing entity based in the UK reported in 2022, according to research undertaken by Crohn's & Colitis UK, that the number of individuals in the UK managing Inflammatory Bowel Disease (IBD) reached 500,000, approximately double the figures previously suggested; consequently, this surge in IBD cases is set to boost the development trajectory of the colorectal cancer molecular diagnostic industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

Which Emerging Trends Are Transforming the Colorectal Cancer Molecular Diagnostics Market in 2025?
Leading entities within the colorectal cancer molecular diagnostics sector are concentrating their efforts on creating novel molecular diagnostic methods and tailored treatment strategies, typified by the Shield Blood Test concept aimed at detecting colorectal cancer when it is in its initial, more manageable phases. This Shield Blood Test represents a preliminary blood screening tool engineered specifically for the identification of early-stage colorectal cancer (CRC). Illustratively, in May of 2022, Guardant Health, an American biotechnology firm specializing in oncology molecular diagnostic offerings, introduced its Shield Blood Test. This non-invasive screening method offers an accessible alternative by requiring only a straightforward blood sample, thereby mitigating barriers associated with patient reluctance toward undergoing standard screening procedures. Performance evaluations demonstrated the test achieved a 91% sensitivity rate for pinpointing colorectal cancer and a 20% sensitivity for detecting advanced adenomas, coupled with a specificity rating of 92%. The assay's capability to flag nascent colorectal cancer indicators in the bloodstream is established through analysis derived from comprehensive groups encompassing more than 2,000 individuals diagnosed with colorectal cancer, 357 with advanced adenoma, and 3,757 healthy control subjects.

What Are the Key Segments in the Colorectal Cancer Molecular Diagnostics Market?
The colorectal cancer molecular diagnosticsmarket covered in this report is segmented -

1) By Type: Instruments; Reagents And Kits; Services
2) By Technology: Polymerase Chain Reaction (PCR); Sequencing; Mass Spectrometry; Transcription Mediated Amplification; Chips And Microarrays; Isothermal Nucleic Acid Amplification Technology (INAAT)
3) By End Users: Hospitals; Ambulatory Surgical Centers; Diagnostic Laboratories; Homecare Settings

Subsegments:
1) By Instruments: PCR Machines; Sequencers; Microarrays
2) By Reagents And Kits: DNA Or RNA Extraction Kits; Assay Kits; Reagent Packs
3) By Services: Diagnostic Testing Services; Genetic Testing Services; Consultation Services

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp

Who Are the Key Players Shaping the Colorectal Cancer Molecular Diagnostics Market's Competitive Landscape?
Major companies operating in the colorectal cancer molecular diagnostics market report are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton inson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

What Geographic Markets Are Powering Growth in the Colorectal Cancer Molecular Diagnostics Market?
North America was the largest region in the colorectal cancer molecular diagnostics market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13120

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.